Last reviewed · How we verify
Artesunate-amodiaquine given with single low dose primaquine
Artesunate-amodiaquine given with single low dose primaquine is a Small molecule drug developed by Professor Anders Björkman. It is currently FDA-approved.
At a glance
| Generic name | Artesunate-amodiaquine given with single low dose primaquine |
|---|---|
| Sponsor | Professor Anders Björkman |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Artesunate-amodiaquine given with single low dose primaquine CI brief — competitive landscape report
- Artesunate-amodiaquine given with single low dose primaquine updates RSS · CI watch RSS
- Professor Anders Björkman portfolio CI
Frequently asked questions about Artesunate-amodiaquine given with single low dose primaquine
What is Artesunate-amodiaquine given with single low dose primaquine?
Artesunate-amodiaquine given with single low dose primaquine is a Small molecule drug developed by Professor Anders Björkman.
Who makes Artesunate-amodiaquine given with single low dose primaquine?
Artesunate-amodiaquine given with single low dose primaquine is developed and marketed by Professor Anders Björkman (see full Professor Anders Björkman pipeline at /company/professor-anders-bj-rkman).
What development phase is Artesunate-amodiaquine given with single low dose primaquine in?
Artesunate-amodiaquine given with single low dose primaquine is FDA-approved (marketed).